

Complete if Known

(Use as many sheets as necessary)

Street	1	of	4
--------	---	----	---

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

U.S. PATENT DOCUMENTS

RECEIVED
AUG 04 2003
TECH CENTER 1600/2900

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SAD		5152997	10/06/92	Ebert, et al.	
		5231087	07/27/93	Thornfeldt	
		5256652	10/26/93	El Rashidy	
		5324521	06/28/94	Gertner, et al.	
		5326790	07/05/94	Thornfeldt	
		5332577	07/26/94	Gertner, et al.	
		5340586	08/23/94	Pike, et al.	
		5362497	11/08/94	Yamada, et al.	
		5413794	05/09/95	Suzuki, et al.	
		5446070	08/29/95	Mantelle	
		5460820	10/24/95	Ebert, et al.	
		5610150	03/11/97	Labrie	
		5629021	05/13/97	Wright	
		5641504	06/24/97	Lee, et al.	
		5643899	07/01/97	Elias, et al.	
		5648350	07/15/97	DeLingnieres	
		5651973	07/29/97	Moo-Young, et al.	
		5654337	08/05/97	Roentsch, et al.	
		5656286	08/12/97	Miranda, et al.	
		5708038	01/13/98	Davis	
		5716638	02/10/98	Touitou	
		5719197	02/17/98	Kanios, et al.	
		5723114	03/03/98	Thornfeldt, et al.	
		5730987	03/1998	Omar	
		5744162	04/28/98	Okabe, et al.	
		5760096	06/02/98	Thornfeldt, et al.	
		5770606	06/23/98	El Rashidy, et al.	
		5776923	07/07/98	Labrie	
		5788983	08/04/98	Chien, et al.	
		5807849	09/15/98	Labrie	
		5807957	09/15/98	Samour, et al.	
		5837289	11/17/98	Grasela, et al.	
		5847128	12/08/98	Martin, et al.	
		5855905	01/05/99	Oettel, et al.	
		5874074	02/23/99	Smith	
		5908619	06/01/99	Scholz	

RECEIVED
AUG 04 2003
TECH CENTER 1600/2900

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SAD		5908638	06/01/99	Huber, et al.	
		5932227	08/03/99	Higo, et al.	
		5955455	09/21/99	Labrie	
		5968919	10/19/99	Samour, et al.	
		6010716	01/04/00	Saunal, et al.	
		6019997	02/01/00	Scholz, et al.	
		6037346	03/14/00	Doherty, Jr., et al.	
		6075028	06/13/00	Graham	
		6077841	06/20/00	Sui, et al.	
		6087368	07/11/00	Macor, et al.	
		6117446	09/12/00	Place	
		6127363	10/03/00	Doherty, et al.	
		6156753	12/05/00	Doherty, et al.	
		6238284	05/29/01	Dittgen, et al.	
		6299900	10/09/01	Reed, et al.	

RECEIVED

AUG 04 2003

TECH CENTER 1800/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1*
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SAD		DE 3238984	10/21/82	Besins		
		EPO 0197753	10/15/96	Keenan, et al.		
		EPO 0581587 A2	02/02/94	Kobayashi, et al.		
		EPO 0804926	04/19/97	Jenapharm GMBH		
		FR 2515041	04/29/83	Besins		
		FR 2518879	07/01/83	Besins		
		FR 2519252	07/08/83	Besins		
		FR 2705572	02/12/94	Besins		
		GB 2109231	06/02/83	Besins		
		WO 0024362	05/04/00	Univ. Virginia Commonwealth		
		WO 0066870 A1	08/10/00	Lulla, et al.		
		WO 0076522 A1	12/21/00	Watson Pharm. Inc.		
		WO 0143775 A1	06/21/01	Luo, et al.		
		WO 9325168 A1	12/23/93	Heiber, et al.		
		WO 9325168 A1	12/23/93	Theratch Inc.		
		WO 9408590	04/28/94	BTG Pharm. Corp.		

Date
Considered

10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SAD		WO 9421230	09/28/94	Cellegy Pharm Inc		
		WO 9421271	09/29/94	Cellegy Pharm Inc		
		WO 9627372 A1	09/12/96	Int'l Medical		
		WO 9636339	11/21/96	Beth Israel Hosp		
		WO 9743989	11/27/97	Diversified Pharm Inc		
		WO 9808547	03/05/98	Seikisui Chemical Co Ltd		
		WO 9824451	06/11/98	Bio Technology General Corp		
		WO 9834621 A1	08/13/98	Rako		
		WO 9837871	09/03/98	Minnesota Mining & Mfg		
		WO 9924041 A1	05/20/99	Cellegy		
		WO 9932107	07/01/99	West Pharm Serv Drug Res Ltd		
		WO 9966870 A1	12/29/99	Fotinos		

RECEIVED
AUG 04 2003
TECH CENTER 1600/2900

	SAD	Date Considered	10/8/03
--	-----	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/033,101
Filing Date 10/19/2001
First Named Inventor Robert E. Dudley
Art Unit 1617
Examiner Name Jiang, S.
Attorney Docket Number 01917590

RECEIVED

AUG 04 2003

NON PATENT LITERATURE

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

TECH CENTER 1600/2900

- ABITBOL, et al., *Sex Hormones and the Female Voice*, J VOICE, 1999 Sep; 13(3): 424-46.
- AHMED, et al., *Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism*, J CLIN ENDOCRINOL METAB, 1988 Mar; 66(3): 546-51.
- AKIMOTO, et al., *Relationship Between Diurnal Rhythm of Serum Testosterone and Prostatic Markers (PSA and PAP) in Untreated Prostate Cancer*, UROLOGY, 1994 Mar; 43(3): 337-41.
- ALEXANDER, et al., *Sex Steroids, Sexual Behavior, and Selection Attention for Erotic Stimuli in Women Using Oral Contraceptives*, PSYCHONEUROENDOCRINOLOGY, 1993; 18(2): 91-102.
- ALEXANDER, et al., *Testosterone and Sexual Behavior in Oral Contraceptive Users and Nonusers: a Prospective Study*, HORM BEHAV, 1990 Sep; 24(3): 388-402.
- ALIVIZATOS, et al., *Update of Hormonal Treatment in Cancer of the Prostate*, ANTICANCER DRUGS, 1993 Jun; 4(3):301-9.
- ALMEIDA, *Sex Playing with the Mind. Effects of Oestrogen and Testosterone Mood and Cognition*, ARQ NEUROPSIQUIATR, 1999 Sept; 57(3A): 701-6.
- ANDERSON, et al, *The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men*, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 75, No. 6, p.1503 (1992).
- ANGOLD, et al., *Pubertal Changes in Hormone Levels and Depression in Girls*, PSYCHOL MED 1999 Sep; 29(5): 1043-53.
- ARVER, et al., *Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System*, J UROL, 1996 May; 155(5): 1604-8.
- ARVER, et al., *Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men*, CLINICAL ENDOCRINOLOGY, 47: 727-737 (1997).
- BAGATELL, et al., *Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men*, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 78, No. 3, pp. 711 (1994).
- BALS-PRATSCH, et al., *Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year*, ACTA ENDOCRINOLOGICA (COPENH) 1988, 118: 7-13.
- BALS-PRATSCH, et al., *Transdermal Testosterone Substitution Therapy for Male Hypogonadism*, LANCET, 1986 Oct 25; 2(8513): 943-6.
- BANCROFT, *Endocrinology of Sexual Function*, CLINICS IN OBSTETRICS AND GYNAECOLOGY, Vol. 7, No. 2, August 1980, p. 253.
- BANCROFT, et al., *Androgens and the Menopause; a Study of 40-60-Year-Old Women*, CLIN ENDOCRINOL (OXF), 1996 Nov; 45(5): 577-87.
- BANCROFT, et al., *Mood, Sexuality, Hormones, and the Menstrual Cycle. III. Sexual. and the Role of Androgens.*, PSYCHOSOM MED, 1983 Dec; 45(6): 509-16.
- BARRETT-CONNER, et al., *A Two-Year, Double-Blind Comparison of Estrogen-Androgen and Conjugated Estrogens in Surgically Menopausal Women. Effects Bone Mineral Density, Symptoms and Lipid Profiles*, J REPROD MED, 1999 Dec; 44(12): 1012-20.
- BARRETT-CONNER, et al., *Cognitive Function and Endogenous Sex Hormones in Older Women*, J AM GERIATR SOC, 1999 Nov; 47(11): 1289-93.

Date
Considered

10/18/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/033,101	RECEIVED AUG 04 2003 TECH CENTER 1600/2900
Filing Date	10/19/2001	
First Named Inventor	Robert E. Dudley	
Art Unit	1617	
Examiner Name	Jiang, S.	
Attorney Docket Number	01917590	

Sheet

2

of

19

NON PATENT LITERATURE

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

BARTNOF, Testosterone Therapy Causes Menstruation to Return in Women with AIDS-Related Wasting, www.hivandhepatitis.com (10/12/99).

BARTSCH, et al., Interrelationships Between Sex Hormone-Binding Globulin and 17 beta-Estradiol, Testosterone, 5 alpha-Dihydrotestosterone, Thyroxine, and Triiodothyronine in Prepubertal and Pubertal Girls, J CLIN ENDOCRINOL METAB, 1980 Jun; 50(6): 1053-1056

BARTSCH, et al., Sex Hormone Binding Globulin Binding Capacity, Testosterone, 5alpha-Dihydrotestosterone, Oestradiol and Prolactin in Plasma of Patients with Prostatic Carcinoma under Various Types of Hormonal Treatment, ACTA ENDOCRINOL (COPENH), 1977 Jul; 85(3): 650-64.

BARTSCH, Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men, MATURITAS, 1980 Jul; 2(2): 109-118.

BASSON, et al., Androgen Replacement for Women, CANADIAN FAMILY PHYSICIAN, Vol. 45: September 1999, pp. 2100-2107.

BAUMGARTNER, et al., Predictors of Skeletal Muscle Mass in Elderly Men and Women, MECH AGEING DEV, 1999 Mar 1; 107(2): 123-36.

BEHRE, et al., Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies, EUROPEAN JOURNAL OF ENDOCRINOLOGY (1999) 140 414-419.

BEHRE, et al., Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 82, No. 8, pp. 2389 1997.

BEHRE, et al., Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years, CLINICAL ENDOCRINOLOGY (1999) 50, 629-635.

BEHRE, et al., Prostate Volume in Testosterone-Treated and Untreated Hypogonadal Men in Comparison to Age-Matched Normal Controls, CLIN ENDOCRINOL (OXF), 1994 Mar; 40(3): 341-9.

BEHRE, et al., Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester, JOURNAL OF ENDOCRINOLOGY AND METABOLISM, Vol. 75, No. 5, pp. 1204-1210 (1992).

BELGOROSKY, et al., Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys, J STEROID BIOCHEM, 1987; 27(1-3): 291-295.

BELGOROSKY, et al., Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones, J STEROID BIOCHEM, 1983 Jun; 18(6): 783-787.

BELGOROSKY, et al., Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Prepuberty in Boys, J CLIN ENDOCRINOL METAB, 1986 Aug; 63(2): 510-512.

BELGOROSKY, Sex Hormone Binding Globulin Response to Testosterone. An Androgen Sensitivity Test, ACTA ENDOCRINOL (COPENH), 1985 May; 109(1): 130-138.

BERNER, et al., Pharmacokinetic Characterisation of Transdermal Delivery System, CLIN PHARMACOKINET, 1994 Feb; 26(2): 121-34.

BERNINI, et al., Endogenous Androgens and Carotid Intimal-Medial Thickness in Women, J CLIN ENDOCRINOL METAB, 1999 Jun; 84(6): 2008-12.

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known**RECEIVED**

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

AUG 04 2003

TECH CENTER 1600/2900

Sheet 1 of 19

NON PATENT LITERATUREExaminer
InitialsCite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

- 390 BHASIN, *Clinical Review 34, Androgen Treatment of Hypogonadal Men*, JOURNAL OF CLINICAL Endocrinology and Metabolism, Vol. 74, No. 6, pp. 1221-1225 (1992).
- 390 BHASIN, et al., *A Biodegradable Testosterone Microcapsule Formulation Providing Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men*, J CLIN ENDOCRINOL METAB, 1992 Jan; 74(1): 75-83.
- 390 BHASIN, et al., *Therapeutic Perspective, Issues in Testosterone Replacement in Older Men*, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 83, No. 10, pp. 3435-3448 (1998)
- 390 BISSCHOP, et al., *Effects of Nandrolone Decanoate on Respiratory and Peripheral Muscles in Male and Female Rats*, www.uth.tms.edu. (1996, Downloaded 10/8/98).
- 390 BLOCH, et al. *Pituitary-Adrenal Hormones and Testosterone Across the Menstrual Cycle in Women with Premenstrual Syndrome and Controls*, BIOL PSYCHIATRY, 1998 Jun 15; 43(12): 897-903.
- BOCCHINFUSO, et al., *Expression and Differential Glycosylation of Human Sex Hormone-Binding Globulin by Mammalian Cell Lines*, MOL ENDOCRINOL, 1991 Nov; 5(11): 1723-1729.
- BONNEY, *Hormone Replacement Therapy for Men*, AMERICAN CLINICAL LABORATORY, November/December 1997, <http://iscpubs.com/pubs/acl/acl1197.html>
- BOOJI, et al., *Androgens as Adjuvant Treatment in Postmenopausal Female Patients with Rheumatoid Arthritis*, ANN RHEUM DIS, 1996 Nov; 55(11): 811-5.
- BOOTS, et al., *Measurement of Total Serum Testosterone Levels Using Commercially Available Kits: High Degree of Between-Kit Variability*, FERTIL STERIL, 1988 Feb; 69(2): 286-292.
- BOYLE, et al., *Serum Testosterone Measurements*, AM J CLIN PATHOL, 1984 Jun; 81(6): 754,761.
- BROCKS, et al., *Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose*, J CLIN PHARMACOL 1996; 36:732-739.
- BRUUN, et al., *Dihydrotestosterone Measured in Core Biopsies from Prostatic Tissues*, AM J CLIN ONCOL, 1988; 11 Suppl 2:S27-9.
- BUCKLER, et al. *The Effects of Low-Dose Testosterone Treatment on Lipid Metabolism, Clotting Factors and Ultrasonographic Ovarian Morphology in Women*, CLINICAL ENDOCRINOLOGY (1997) 49, 173-178.
- BUCKLER, et al., *Which Androgen Replacement Therapy for Women?*, J CLIN ENDOCRINOL METAB, 1998 Nov; 83(11):3920-4.
- BURGER, et al., *Effect of Combined Implants of Oestradiol and Testosterone on in Postmenopausal Women*, BR MED J (CLIN RES ED), 1987 Apr 11; 294(6577): 936-7.
- BURGER, et al., *The Management of Persistent Menopausal Symptoms with Oestradiol-Testosterone Implants: Clinical, Lipid and Hormonal Results*, MATURITAS, 1984 Dec; 6(4): 351-8.
- CAREY, et al., *Transdermal Testosterone Treatment of Hypogonadal Men*, THE JOURNAL OF UROLOGY, Vol. 140, pp. 76-79, (July 1988).
- CARLSTROM, et al., *Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function*, INTERNATIONAL JOURNAL OF ANDROLOGY, 1990, 13, pp. 67-73.
- 390 CASHDAN, *Hormones, Sex and Status in Women*, HORMONES AND BEHAVIOR, 29, 354-366 (1995).

Date
Considered

10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/033,101
		Filing Date	10/19/2001
		First Named Inventor	Robert E. Dudley
		Art Unit	1617
		Examiner Name	Jiang, S.
		Attorney Docket Number	01917590
Sheet 1 of 19	AUG 04 2003 TECH CENTER 1600/2901		
NON PATENT LITERATURE			
Examiner Initials	No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
SEP		CASSON, et al., <i>Androgen Replacement Therapy in Women: Myths and Realities</i> , INT J FERTIL MENOPAUSAL STUD; 1996 Jul-Aug; 41(4):412-22.	
		CHAKRAVARTI, et al., <i>Endocrine Changes and Symptomatology After Oophorectomy in Premenopausal Women</i> , BR J OBSTET GYNAECOL, 1977 Oct; 84(10): 769-75.	
		CHEMANA, et al., <i>Percutaneous Absorption of 5-dihydrotestosterone in Man II. Percutaneous Administration of 5-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis; Clinical, Metabolic and Hormonal Effectiveness</i> , INTERNATIONAL JOURNAL OF ANDROLOGY, 5 (1982) 595-606.	
		CHERRIER, et al., <i>T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men</i> (6/7/99).	
		CHOI, et al., <i>Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus</i> , J UROL, 1993 Aug; 150(2 Pt 2): 657-660.	
		COFRANCESCO, Jr., et al., <i>Transdermal Testosterone Delivery Systems</i> , THE ENDOCRINOLOGIST, Vol. 6, No. 3, pp. 207-213.	
		CONWAY, et al., <i>Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men</i> , INT J ANDROL, 1988 Aug; 11(4): 247-64.	
		COOPER, et al., <i>Effect of Fatty Acids and Alcohols on the Penetration of Acyclovir Across Human Skin in Vitro</i> , Journal of Pharmaceutical Sciences, Vol. 74, No. 6, pp. 688-689 (June 1985).	
		CUNNINGHAM, et al., <i>Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status</i> , JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 58, No. 5, pp. 915-918 (1984).	
		CUNNINGHAM, et al., <i>Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men</i> , JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 70, No. 3, 792-797.	
		CUNNINGHAM, et al., <i>Testosterone Transdermal Delivery System</i> , PHARMACOLOGY, BIOLOGY, AND CLINICAL APPLICATIONS OF ANDROGENS; 42:437-447 1996 Wiley-Liss, Inc.	
		CUNNINGHAM, et al., <i>Testosterone Replacement with Transdermal Therapeutic System, Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels</i> , JAMA, 1989 May 5; 261(17): 2525-30.	
		CUTOLO, et al., <i>Hypothalamic-Pituitary-Adrenocortical Axis Function in Premenopausal Women with Rheumatoid Arthritis Not Treated with Glucocorticoids</i> , J RHEUMATOL, 1999 Feb; 26(2): 282-8.	
		DAMASSA, et al., <i>Sex Hormone-Binding Globulin and Male Sexual Development</i> , NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, Vol. 19, No. 2, pp. 165-175 (1995).	
		DAVIDSON, et al., <i>Hormonal Changes and Sexual Function in Aging Men</i> , JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 57, No. 1, pp. 71-77 (1983)	
		DAVIDSON, et al., <i>Hormonal Replacement and Sexuality in Men</i> , CLINICS IN ENDOCRINOLOGY AND METABOLISM, Vol. 11, No. 3, pp. 599-623 (November 1982).	
		DAVIS, <i>Androgen Replacement in Women: a Commentary</i> , J CLIN ENDOCRINOL METAB, 1999 Jun; 84(6): 1886-91.	
SEP		DAVIS, et al., <i>Clinical Review 82: Androgens and the Postmenopausal Woman</i> , J. CLIN ENDOCRINOL METAB, 1996 Aug; 81(8): 2759-63.	
		Date Considered	10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/033,101
		Filing Date	10/19/2001
		First Named Inventor	Robert E. Dudley
		Art Unit	1617
		Examiner Name	Jiang, S.
		Attorney Docket Number	01917590
Sheet	19	RECEIVED AUG 04 2003 TECH CENTER 1600/290	
NON PATENT LITERATURE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
Examiner's Initials*	Citation No.		
SPD		DAVIS, et al., <i>Testosterone Enhances Estradiol's Effects on Postmenopausal Bone Density and Sexuality</i> , MATURITAS, 1995 Apr; 21(3): 227-36.	
		DAVIS, et al., <i>Use of Androgens in Postmenopausal Women</i> , CURR OPIN OBSTET GYNECOL, 1997 Jun; 9(3): 177-80.	
		DE LIGNIERES, et al., <i>Treatment of Male Hypogonadism by Topical Administration of Androgens</i> , ANNALS OF MEDICINE 25: 235-241, 1993.	
		DE LIGNIERES, <i>Transdermal Dihydrotestosterone Treatment of Andropause</i> , ANNALS OF MEDICINE 25: 235-241, 1993.	
		DE LUNARDO, et al., <i>Determination of Acceptability of 2 Cutaneous Estradiol Gels, In A Dose of 1.5 mg Daily</i> , J. Gynecol. Obstet. Biol. Reprod. (Paris), Vol. 29, No. pp. 509-516, (September 2000)	
		DENIS, <i>Future Implications for the Management of Benign Prostatic Hyperplasia</i> , EUR UROL, 1994; 25 Suppl 1:29-34.	
		DOBS, et al., <i>Pharmacokinetics, Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men</i> , THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 84, No. 10, pp. 3469-3478 (1999).	
		DOBS, <i>Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men</i> , J CLIN ENDOCRINOL METAB, 1999 Oct; 84(10): 3469-78.	
SPD		DOUCHI, et al., <i>Serum Androgen Levels and Muscle Mass in Women with Polycystic Ovary Syndrome</i> , OBSTETRICS & GYNECOLOGY, Vol. 94, No. 3, pp. 337-340 (1999).	
		Dr. N's Menopause & Hysterectomy Resource Page, http://www.menopausehysterectomy.com/methods.htm	
SPD		DRAFTA, et al., <i>The Effects of Endocrine Therapy on Plasma Steroids in Prostatic Carcinoma Patients</i> , ENDOCRINOLOGY, 1984 Jul-Sep; 22(3): 191-7.	
		DRAKE, et al., <i>Associations Between Circulating Sex Steroid Hormones and Cognition in Normal Elderly Women</i> , NEUROLOGY, 2000 Feb; 54(3): 599-603.	
		ENDO 99: <i>Testosterone Patch Effective for Diminished Sexual Function in Surgically Menopausal Women</i> , DOCTOR'S GUIDE TO THE INTERNET, http://www.docguide.com , June 15, 1999.	
		ENDO 99: <i>Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women</i> , www.pslgroup.com (June 15, 1999).	
		ERIKSSON, et al., <i>Serum Levels of Androgens are Higher in Women with Premenstrual Irritability and Dysphoria than in Controls</i> , PSYCHONEUROENDOCRINOLOGY, 1992 May-Jul; 17(2-3): 195-204.	
SPD		ERNESTI, et al., <i>Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture</i> , SKIN PHARMACOL, 1992; 5(3): 146-153.	
		<i>Estrogel</i> , www.netdoktor.dk/medicin/Fakta/Estrogel . (Downloaded 6/26/04).	
SPD		EWING, et al., <i>Dihydrotestosterone Concentration of Beagle Prostatic Tissue: Effect of Age and Hyperplasia</i> , ENDOCRINOLOGY, 1983 Dec; 113(6): 2004-9.	
SPD		EXTON, et al., <i>Cardiovascular and Endocrine Alternations after Masturbation-Induced Orgasm in Women</i> , PSYCHOSOM MED, 1999 May-Jun; 61(3): 280-9.	

SPD	Date Considered	10/8/03
-----	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) JUL 30 2003 PATENT & TRADEMARK OFFICE		Application Number	10/033,101		
		Filing Date	10/19/2001		
		First Named Inventor	Robert E. Dudley		
		Art Unit	1617		
		Examiner Name	Jiang, S.		
		Attorney Docket Number	01917590		
Sheet	6	of	19	TECH CENTER 1600/2900	

NON PATENT LITERATURE	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

340	FAHRNER, et al., <i>Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)</i> , INT J SPORTS MED, 1998 Jan; 19(1): 12-15.
	FINDLAY, et al., <i>Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone</i> , J CLIN ENDOCRINOL METAB, 1989 Feb; 68(2): 369-373.
	FLOTTER, et al., <i>Administration of Testosterone Undecanoate in Postmenopausal Women: Effects on Androgens, Estradiol, and Gonadotrophins.</i> , MENOPAUSE, 2000 Jul-Aug; 7(4): 251-6.
	FOURNIER, et al., <i>Value of a Percutaneous Estrogen Solution in Stopping Lactation</i> , Rev. Fr. Gynecol. Obstet., Vol. 85, No. 12, pp. 715-719 (December 1990).
	GAIDANO, et al., <i>Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty</i> , CLIN CHIM ACTA, 1980 Jan 15; 100(2): 91-97.
	GANN, et al., <i>Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer</i> , J NATL CANCER INST, 1996 Aug 21; 88(16): 1118-26.
	GANN, et al., <i>Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer</i> , J NATL CANCER INST, 1996 Aug 21; 88(16): 1118-1126.
	GARNETT, et al., <i>A Cross-Sectional Study of the Effects of Long-Term Percutaneous Hormone Replacement Therapy on Bone Density</i> , OBSTET GYNECOL, 1991 Dec; 78(6): 1002-7.
	GARNETT, et al., <i>The Effects of Plasma Estradiol Levels on Increases in Vertebral Femoral Bone Density Following Therapy with Estradiol and Estradiol with Testosterone Implants</i> , OBSTET GYNECOL, 1992 Jun; 79(6): 968-72.
	GEFAEL, <i>Graeme's Testosterone Page</i> , www.voyager.co.nz (5/12/00).
	GELLER, <i>Basis for Hormonal Management of Advanced Prostate Cancer</i> , CANCER, 1993 Feb 1; 71(3 Suppl): 1039-45.
	GELLER, et al., <i>DHT in Prostate Cancer Tissue □ a Guide to Management and Therapy</i> , PROSTATE, 1985; 6(1):19-25.
	GELLER, <i>Nonsurgical Treatment of Prostatic Hyperplasia</i> , CANCER, 1992 Jul 1; 70(1 Suppl): 339-45.
	GELLER, <i>Pathogenesis and Medical Treatment of Benign Prostatic Hyperplasia</i> , PROSTATE SUPPL, 1989; 2:95-104.
	GENNARO, <i>Remington: The Science and Practice of Pharmacy</i> , 20 th Edition, Chapter 44, pp. 842-843 (2000).
	GOGGIN, et al., <i>The Relationship of Mood, Endocrine, and Sexual Disorders in Human Immunodeficiency Virus Positive (HIV+) Women: an Exploratory Study</i> , PSYCHOSOM MED, 1998 Jan-Feb; 60(1): 11-6.
	GONZALEZ-SAGRADO, et al., <i>Reference Values and Methods Comparison of a New Testosterone Assay on the AxSYM System</i> , CLIN BIOCHEM, 2000 Apr; 33(3): 175-9.
	GOOD, et al., <i>Bone Mineral Density and Body Composition in Lean Women with Polycystic Ovary Syndrome</i> , FERTIL STERIL, 1999 Jul; 72(1): 21-5.
530	GOODMAN, et al., <i>Action of Skin Permeation Enhancers Azone, Oleic Acid and Decylmethyl Sulphoxide: Permeation and DSC Studies.</i>

	Date Considered	10/8/03
--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449/PTO		Complete if Known		RECEIVED AUG 04 2003 TECH CENTER 1600/2900
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) JUL 30 2003 U.S. PATENT & TRADEMARK OFFICE		Application Number	10/033,101	
		Filing Date	10/19/2001	
		First Named Inventor	Robert E. Dudley	
		Art Unit	1617	
		Examiner Name	Jiang, S.	
Sheet	of	19	Attorney Docket Number	01917590

NON PATENT LITERATURE	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
SA	GOOREN, A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate, 1994 May-Jun; 15(3):212-5.
	GOOREN, Androgen Levels and Sex Functions in Testosterone-Treated Hypogonadal Men, ARCHIVES OF SEXUAL BEHAVIOR, Vol. 16, No. 6, p.463-473 (1987).
	GOUCHIE, et al., The Relationship Between Testosterone Levels and Cognitive Ability Patterns, PSYCHONEUROENDOCRINOLOGY, 1991; 16(4): 323-34.
	GREENDALE, et al., Endogenous Sex Steroids and Bone Mineral Density in Older Women and Men: the Rancho Bernardo Study, J BONE MINER RES, 1997 Nov; 12(11): 1833-43.
	GRINSPOON, et al, Body Composition and Endocrine Function in Women with Acquired Immunodeficiency Syndrome Wasting, J. CLIN ENDOCRINOL METAB, 1997 May; 82(5): 1332-7.
	GRUBER, et al., Effect of Percutaneous Androgen Replacement Therapy on Body Composition and Body Weight in Postmenopausal Women, MATURITAS 29 (1998) 253-259.
	HANDELSMAN, et al., Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 70, No. 1., pp. 216-222 (1990).
	HARDY, et al., Endocrine Assessment of Impotence □ Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin, POSTGRAD MED J (1994) 70, 836-837.
	HEIKKILA, et al., Serum Androgen-Anabolic Hormones and the Risk of Rheumatoid Arthritis, ANN RHEUM DIS, 1998 May; 57(5): 281-5.
	HEISS, et al., Associations of Body Fat Distribution, Circulating Sex Hormones Bone Density in Postmenopausal Women, J CLIN ENDOCRINOL METAB, 1995 May; 80(5): 1591-6.
	HOLOWNIA, et al., A Clinical Evaluation of a Direct Radioimmunoassay of Testosterone; CLIN CHIM ACTA, 1993 Jan 31; 214(1): 31-43.
	HOWLAND, The "Other" Hormone Replacement Therapy: Testosterone in Menopausal Women, HealthGate, www.bewell.com (8/7/00).
	IQBAL, et al., Binding of Testosterone and Oestradiol to Sex Hormone Binding Globulin, Human Serum Albumin and Other Plasma Proteins: Evidence for Non-Specific Binding of Oestradiol to Sex Hormone Binding Globulin, CLIN SCI, 1983 Mar; 64(3): 307-314.
	ISAACS, et al., Etiology and Disease Process of Benign Prostatic Hyperplasia, PROSTATE SUPPL, 1989; 2:33-50.
	ISAACS, Etiology of Benign Prostatic Hyperplasia, EUR UROL, 1994; 25 Suppl 1:6-9.
	ITOH, et al., The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level, NIPPON NAIBUNPI GAKKAI ZASSHI, 1991 Jan 20; 67(1): 23-22
	JAFFE, et al., Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men, HORM RES, 1994;41:215-217.
	JARKANDER-ROLFF, et al., Transdermal Application of A Testosterone Gel – A Pharmacokinetic Study.
SA	JAVANBAKHT, et al., Pharmacokinetics of a Novel Testosterone Matrix Transdermal System in Healthy, Premenopausal Women and Women Infected with the Human Immunodeficiency Virus, J CLIN ENDOCRINOL METAB, 2000 Jul; 85(7): 2395-401.

	Date Considered	10/8/03
--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED

Substitute for form 1449/PTO

C mplete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 19

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

AUG 04 2003

TECH CENTER 1600/290

NON PATENT LITERATURE

Examiner
Initials*Cite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

- JOCKENHOVEL, et al., *Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men*, CLINICAL ENDOCRINOLOGY, (1996) 45 61-71.
- KALANTARIDOU, et al., *Transdermal Testosterone Replacement for Young Women with Spontaneous Premature Ovarian Failure: A Pilot Study*, No. 2322, www.abstracts-on-1 (Downloaded 8/7/00).
- KAO, et al., *Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture*, J PHARMACOL EXP THER, 1987 May; 241(2): 482-487.
- KARR, et al., *Induction of Benign Prostatic Hypertrophy in Baboons*, UROLOGY, 1984 Mar; 23(3): 276-89.
- KASPER, et al., *Development, Progression, and Androgen-Dependence of Prostate Tumors in Probasin-Large T Antigen Transgenic Mice: a Model for Prostate Cancer*, LAB INVEST, 1998 Mar; 78(3): 319-333.
- KAUFMAN, *Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation*, International Journal of Impotence Research, Vol. 12, Supplement 3, p. S75 (B9) (September 2000).
- KHOSLA, et al., *Relationship of Serum Sex Steroid Levels and Bone Turnover with Bone Mineral density in Men and Women: a Key Role for Bioavailable Estrogen*, J CLIN ENDOCRINOL METAB, 1998 Jul; 83(7): 2266-74.
- KIRSCHNER, et al., *Androgen-Estrogen Metabolism in Women with Upper Body Versus Lower Body Obesity*, J CLIN ENDOCRINOL METAB, 1990 Feb; 70(2): 473-9.
- KLUGO, et al., *Response of Micropenis to Topical Testosterone and Gonadotropin*, THE JOURNAL OF UROLOGY, Vol. 119, May, pp. 667-668. (1978).
- KNUSSMANN, et al., *Relations Between Sex Hormone Levels and Sexual Behavior in Men*, ARCHIVES OF SEXUAL BEHAVIOR, Vol. 15, No.5, p. 429 (1986).
- KORENMAN, et al., *Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems*, AM J MED, 1987 Sept; 83(3): 471-478.
- KRAEMER, et al., *Orgasmic Frequency and Plasma Testosterone Levels in Normal Human Males*, ARCHIVES OF SEXUAL BEHAVIOR, Vol. 5, No. 2, p.125 (1976).
- KRAHE, et al., *Risk Factors for Decreased Bone Density in Premenopausal Women*, BRAZ J MED BIOL RES, 1997 Sep; 30(9): 1061-6.
- KUHN, et al., *Effects of 10 Days Administration of Percutaneous Dihydrotestosterone on the Pituitary-Testicular Axis in Normal Men*, J CLIN ENDOCRINOL METAB, 1984 Feb; 58(2): 231-5.
- KUHN, et al., *Gynecomastia: Effect of Prolonged Treatment with Dihydrotestosterone by the Percutaneous Route*, PRESSE MED, 1983 Jan 8; 12(1): 21-5.
- KUHN, et al., *Traitement Androgenique Percutane des Hypogonadismes Masculins. Efficacite Comparee de la Testosterone et d la Dihydrotestosterone: Etude de 40 Observations*, CONTRACEPTION-FERTILITE-SEXUALITE, Vol. 14, No. 11, pp 1031-1036 (1986).
- LABRIE, et al., *Physiological Changes in Dehydroepiandrosterone are not Reflected by Serum Levels of Active Androgens and Estrogens but of their Metabolites: Intracrinology*, J CLIN ENDOCRINOL METAB, 1997 Aug; 82(8): 2403-2409.
- LACAYO, *Are You Man Enough?*, Time Europe, www.Time.com, Vol. 155, No. 16 (April 24, 2000).

Date
Considered

10/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

RECEIVED

AUG 04 2003

TECH CENTER 1600/2901

Sheet 1 of 19

NON PATENT LITERATURE

Examiner
Initials*Cite
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

LEIBLUM, et al., *Vaginal Atrophy in the Postmenopausal Woman. The Important Sexual Activity and Hormones*, JAMA, 1983 Apr 22-29;249(16): 2195-8.LEIFKE, et al., *Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men*, EUROPEAN JOURNAL OF ENDOCRINOLOGY (1998) 138 51-58.LEINONEN, et al., *Serum Sex Hormone Binding Globulin and Testosterone Binding After Estradiol Administration, Castration, and Their Combination in Men with Prostatic Carcinoma*, INVEST UROL, 1979 Jul; 17(1): 24-27.LEWIS, et al, *Serum 5 α -Dihydrotestosterone and Testosterone Changes with Age in Man*, ACTA ENDOCRINOLOGICA, 82 (1976) 444-448.LEWIS, et al., *Proceedings: Age-Related Changes in Serum 5 α plha-dihydrotestosterone and Testosterone in Normal Men*; J ENDOCRINOL, 1975 Nov; 67(2): 15P.LIAO, *Androgen Action: Molecular Mechanism and Medical Application*, J FORMOS MED ASSOC, 1994 Sep; 93(9): 741-51.LONGCOPE, et al., *Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men*; J CLIN ENDOCRINOL METAB, 1990 Dec; 71(6): 1442-1446.LONGSTRETH, et al., *Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment*, Unimed Pharmaceuticals (October 31, 2000)~~MacroChem Accelerates Development of Top For Impotence, www.pslgroup.com (April 10, 1997).~~MAIBACH, et al., *The Effect of DMSO on Percutaneous Penetration of Hydrocortisone and Testosterone in Man*, Annals New York Academy of Sciences, pp. 423-427.MAN, et al., *Optimization of Physiological Lipid Mixtures for Barrier Repair*, J INVEST DERMATOL, 1996 May; 106(5): 1096-1101.MANOS, *FDA Approves Gel to Treat Low Testosterone Levels*, www.testocrema.com (Downloaded 5/09/01).MANTZOROS, et al, *Contribution of Dihydrotestosterone to Male Sexual Behaviour*, BRITISH MEDICAL JOURNAL, No. 6990, Vol. 310, pp 1289-1291 (May 20, 1995).MANTZOROS, et al., *Leptin Concentrations in the Polycystic Ovary Syndrome*, J CLIN ENDOCRINOL METAB, 1997 Jun; 82(6): 1687-91.MANTZOROS, et al., *Serum Steroids in Relation to Benign Prostatic Hyperplasia*, ONCOLOGY, 1997 Nov-Dec; 54(6):497-501.MARIN, et al., *Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues*, ANDROGENS, MUSCLE AND ADIPOSE TISSUE IN MEN, Vol. 1, NO. 6, pp.329-336 (1992).MASI, *Sex Hormones and Rheumatoid Arthritis: Cause or Effect Relationships in a Complex Pathophysiology?*, CLIN EXP RHEUMATOL, 1995 Mar-Apr; 13(2): 227-40.MASTERS, et al., *Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol*, CLIN CHEM, 1989 Jun; 35(6): 979-984.Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

RECEIVED

AUG 04 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 19

NON PATENT LITERATURE

Examiner
Initials*Cite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

MAZER, et al., *Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men*, JOURNAL OF CONTROLLED RELEASE, 19 (1992) 347-362.MAZER, *New Clinical Applications of Transdermal Testosterone Delivery in Men and Women*, J CONTROLLED RELEASE, 2000 Mar 1; 65(1-2): 303-15.MCCLELLAN, et al., *Transdermal Testosterone*, ADIS NEW DRUG PROFILE DRUGS, 1998 Feb. 55(2): 253-258.MCCLURE, et al., *Hypogonadal Impotence Treated by Transdermal Testosterone*, UROLOGY, Vol. XXXVII, No. 3, pp. 224-228 (March 1991).MCCOY, et al., *A Longitudinal Study of the Effects of Menopause on Sexuality*, MATURITAS, 1985 Sep; 7(3): 203-10.MEAN, et al., *Study on the Binding of Dihydrotestosterone, Testosterone and Oestradiol Sex Hormone Binding Globulin*, CLIN CHIM ACTA, 1977 Oct 1; 80(1): 171-180.MEIKLE, et al., *Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism*, PHARMACOLOGY, BIOLOGY, ANDMEIKLE, et al., *Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men*, J CLIN ENDOCRINOL METAB, 1992 Mar; 74(3): 623-628.MEIKLE, et al., *Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin*, METABOLISM, 1982 Jan; 31(1): 6-9.MEIKLE, et al., *Familial Prostatic Cancer Risk and Low Testosterone*, J CLIN ENDOCRINOL METAB, 1982 Jun; 54(6): 1104-8.MEIKLE, et al., *Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site, A Clinical Research Center Study*, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 81, No. 5, pp. 1832-1840 (1996).MEIKLE, et al., *Prostate Size in Hypogonadal Men Treated with Nonscrotal Permeation-Enhanced Testosterone Transdermal System*, UROLOGY, 1997 Feb; 49(2):191-6.MENDEL, *Rates of Dissociation of Sex Steroid Hormones from Human Sex Hormone-Binding Globulin: a Reassessment*, J STEROID BIOCHEM MOL BIOL, 1990 Oct; 37(2): 251-255.MERMALL, et al., *Temporal (Circadian) and Functional Relationship between Pro Specific Antigen and Testosterone in Healthy Men*, UROLOGY, 1995 Jul; 46(1): 45-53.MILLER, *Benign Prostatic Hyperplasia: Nutritional and Botanical Therapeutic Options*, <http://www.thorne.com/altmedrev/b-p-h.html>MILLER, et al., *Androgen Deficiency in Women with Hypopituitarism*, The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No.2, pp. 561-567 (2001).MILLER, et al., *Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: a Pilot Study*, J CLIN ENDOCRINOL METAB, 1998 Aug; 83(8): 2717-25.MISRA, et al., *Biphasic Testosterone Delivery Profile Observed With Two Different Transdermal Formulations*, Pharmaceutical Research, Vol. 14, No. 9, pp. 1264-1268 (1997).Date
Considered

10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

Sheet 30 of 19

NON PATENT LITERATUREExaminer
Initials

No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

MITCHELL, et al., *Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive*, CLIN ENDOCRINOL (OXF), 1995 May; 42(5): 501-507.

MOLLER, et al., *Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway*, ENDOCRINOLOGY, 1998 Jan; 139(1):213-8.

MOLLGAARD, et al., *Permeation of Estradiol Through the Skin - Effect of Vehicles*, International Journal of Pharmaceutics, Vol. 15, pp. 185-197 (1983).

MOLLGAARD, et al., *Vehicle Effect on Topical Drug Delivery*, Acta Pharm. Suec., Vol. 20, pp. 433-442 (1983).

MOONEY, *Anabolic Steroids For AIDS Therapy: Differences Between Analogs*, No. 1, www.digiweb.com. (July 1998).

MOONEY, *Frequency of Administration - Testosterone & Nandrolone*, Vol. 1, No. 4, www.medibolics.com (Downloaded 10/8/98).

MOORADIAN, et al., *Biological Actions of Androgens*, ENDOCRINE REVIEWS, Vol. 8, No. 1, pp 1-28 (1987).

MORLEY, et al., *Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy*, J. LAB CLIN MED, Vol. 135, No. 5, pp. 370-370 (2000)

MORLEY, et al., *Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men*, METABOLISM, Vol. 46, No. 4 (April 1997), pp. 410-413.

MORRIS, et al., *Marital Sex Frequency and Midcycle Female Testosterone*, ARCH SEX BEHAV, 1987 Feb; 16(1):27-37.

MORRISON, et al., *Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women*, PSYCHOPHARMACOLOGY BULLETIN, 33(2):293-296 (1997).

MYERS, et al., *Effects of Estrogen, Androgen, and Progestin on Sexual Psychophysiology and Behavior in Postmenopausal Women*, J CLIN ENDOCRINOL METAB, 1990 Apr; 70(4): 1124-31.

NAKHLA, et al., *Stimulation of Prostate Cancer Growth by Androgens and Estrogens Through the Intermediacy of Sex Hormone-Binding Globulin*, ENDOCRINOLOGY, 1996 Oct; 137(10): 4126-9.

NAKHLA, et al., *Stimulation of Prostate Cancer Growth by Androgens and Estrogens Through the Intermediacy of Sex Hormone-Binding Globulin*, ENDOCRINOLOGY 1996 Oct; 137(10): 4126-4129.

NANKIN, et al., *Decreased Bioavailable Testosterone in Aging Normal and Impotent Men*, J CLIN ENDOCRINOL METAB, 1986 Dec; 63(6):1418-11420.

NAVARRO, et al., *Salivary Testosterone in Postmenopausal Women with Rheumatoid Arthritis*, J RHEUMATOL, 1998 Jun; 25(6): 1059-62.

NEED, et al., *Double-Blind Placebo-Controlled Trial of Treatment of Osteoporosis with the Anabolic Nandrolone Decanoate*, OSTEOPOROSIS INT (1993) Supl. 1: S218-222.

NEED, et al., *Effects of Nandrolone Therapy on Forearm Bone*, www.medmedia.com (Downloaded 10/8/98).

NEVALAINEN, et al., *Hormone Regulation of Human Prostate in Organ Culture*, CANCER RES, 1993 Nov 1; 53(21):5199-207.

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/033,101
		Filing Date	10/19/2001
		First Named Inventor	Robert E. Dudley
		Art Unit	1617
		Examiner Name	Jiang, S.
		Attorney Docket Number	01917590
Sheet 30	of 19		

NON PATENT LITERATURE	
Examiner Initials & Date	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

SA	NILAS, et al., <i>Bone Mass and its Relationship to Age and the Menopause</i> , J CLIN ENDOCRINOL METAB, 1987 Oct; 64(4): 697-702.
	OSBORNE, D., et al., "Skin Penetration Enhancers Cited in the Technical Literature," Pharmaceutical Technology, pp. 58, 60, 62, 64 & 66 (November 1997).
	OSTRENGA, et al., <i>Significance of Vehicle Composition I: Relationship Between Topical Vehicle Composition, Skin Penetrability, and Clinical Efficacy</i> , Journal of Pharmaceutical Sciences, Vol. 60, No. 8, pp. 1175-1179 (August 1971).
	OSTRENGA, et al., <i>Significance of Vehicle Composition II: Prediction of Optimal Vehicle Composition</i> , Journal of Pharmaceutical Sciences, Vol. 60, No. 8, pp. 1180-1183 (August 1971).
	PADOVA, et al., <i>Pubarche Induction with Testosterone Treatment in Women with Panhypopituitarism</i> , FERTIL STERIL, 1996 Feb; 65(2): 437-9.
	PARKER, et al., <i>Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men</i> , CLINICAL ENDOCRINOLOGY (1999) 50, 57-62.
	PEDERSEN, et al., <i>Relationship Between Sex Hormones, Body Composition and Metabolic Risk Parameters in Premenopausal Women</i> , EUR J ENDOCRINOL, 1995 Aug; 133(2): 200-6.
	PERSKY, et al., <i>Plasma Testosterone Level and Sexual Behavior of Couples</i> , ARCH SEX BEHAV, 1978 May; 7(3): 157-73.
	PERSKY, et al., <i>The Relation of Plasma Androgen Levels to Sexual Behaviors and Attitudes of Women</i> , PSYCHOSOMATIC MEDICINE, Vol. 44, No. 4 (Sept. 1982).
	PETRANGELI, et al., <i>Effects of Two Different Medical Treatments on Dihydrotestosterone Content and Androgen Receptors in Human Benign Prostatic Hyperplasia</i> , J STEROID BIOCHEM, 1988; 30(1-6): 395-9.
	PETROW, <i>The Dihydrotestosterone (DHT) Hypothesis of Prostate Cancer and its Therapeutic Implications</i> , PROSTATE, 1986; 9(4): 343-61.
	PIRKE, et al., <i>Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males</i> ; ACTA ENDOCRINOL (COPENH), 1973 Dec; 74(4): 792-800.
	PLACE, et al., <i>Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone</i> , ANN NY ACAD SCI, 1991; 618:441-9.
	PLYMATE, et al., <i>Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men</i> , J ANDROL, 1989 Sep-Oct; 10(5): 366-71.
	PLYMATE, et al., <i>Effects of Sex Hormone Binding Globulin (SHBG) on Human Prostatic Carcinoma</i> , J STEROID BIOCHEM MOL BIOL, 1991; 40(4-6): 833-839.
	POLLARD, et al., <i>Dihydrotestosterone Does Not Induce Prostate Adenocarcinoma in L-W Rats</i> , PROSTATE, 1987; 10(4):325-31.
SA	RAISZ, et al., <i>Comparison of the Effects of Estrogen Alone and Estrogen Plus Androgen on Biochemical Markers of Bone Formation and Resorption in Postmenopausal Women</i> , JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 81, No. 1, pp. 37-43 (1996).

SA	Date Considered	10/18/03
----	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete if Known

Use as many sheets as necessary)

Sheet

13

of

19

Examiner Initials RAJ Cite 11/1/71

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

RAKO, *Testosterone Deficiency: a Key Factor in the Increased Cardiovascular Risk to Women Following Hysterectomy or with Natural Aging?* J WOMENS HEALTH, 1998 Sep; 7(7): 825-9.

RINGHAM, et al., *Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel In Hypogonadal Men*, Unimed Pharmaceuticals (October 31, 2000).

RODRIGUEZ, *Study of Drug to Preserve Lean Muscle Mass Recruiting Patients*, APLA 9701: Study Recruiting Patients. www.apla.org (Downloaded 10/8/98).

ROSANO, et al, *Antianginal and Lipid Lowering Effect of Chronic Oral Androgen Supplementation in Elderly Male Patients with Coronary Heart Disease*, JACC, Abstract No. 835-4 (February 2001)

ROURU, et al., *Serum Leptin Concentrations in Women with Polycystic Ovary Syndrome*, J CLIN ENDOCRINOL METAB. 1997 Jun; 82(6): 1697-700.

ROUSSEAU, et al, *Inhibition of Steroid-Protein Interactions by Dicyclohexane Derivatives*, J STEROID BIOCHEM. Vol. 31, No. 4B, pp 691-697 (1988).

RUGGS, *Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel*, Unimed News Release, pp. 1-2 (March 31, 1997).

SALEHIAN, et al., *Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate, A Clinical Research Center Study*, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 80, No. 12, pp. 3567-75.

SANDS, et al., *Exogenous Androgens in Postmenopausal Women*, AM J MED, 1995 Jan 16; 98(1A): 76S-79S

SAMVAS, et al, *Increase in Bone Mass after One Year of Percutaneous Oestradiol Testosterone Implants in Post-Menopausal Women Who Have Previously Received Long-Term Oral Oestrogens*, BR J OBSTET GYNAECOL. 1992 Sep; 99(9): 757-60.

CHAISON, et al., *On the Role of Dihydrotestosterone in Regulating Luteinizing Hormone Secretion in Man*. J CLIN ENDOCRINOL METAB. 1980 Nov; 51(5): 1133-1137.

SCHOTTER, et al., *Lignans Interfering with 5 alpha-Dihydrotestosterone Binding to Human Sex Hormone-Binding Globulin*. J NAT PROD. 1988 Jan; 61(1): 119-121.

SCHREINER-ENGEL, et al., *Low Sexual Desire in Women: the Role of Reproductive Hormones*, HORM BEHAV. 1989 Jun; 23(2): 221-34.

SCHREINER-ENGEL, et al., *Sexual Arousability and the Menstrual Cycle*, PSYCHOSOM MED 1981 June; 43(3): 199-214.

SCHURMEYER, et al, *Comparative Pharmacokinetic of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men*, INTERNATIONAL JOURNAL OF ANDROLOGY, 7 (1984) 181-187.

SHANBHAG, et al., *The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma*, J STEROID BIOCHEM, 1986 Feb; 24(2): 549-555.

SHERWIN, *Affective Changes with Estrogen and Androgen Replacement Therapy in Surgically Menopausal Women*. JOURNAL OF AFFECTIVE DISORDERS, 14 (1988) 177-187.

SHERWIN, *Estrogen and/or Androgen Replacement Therapy and Cognitive Functioning in Surgically Menopausal Women*. PSYCHONEUROENDOCRINOLOGY. Vol. 13. NO. 4. pp. 345-357 (1988).

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 19

14

of

19

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

NON PATENT LITERATURE

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

SHERWIN, et al., *Androgen Enhances Sexual Motivation in Females: a Prospective Crossover Study of Sex Steroid Administration in the Surgical Menopause*, PSYCHOSOM MED, 1985 Jul-Aug; 47(4): 339-51.

SHERWIN, et al., *Postmenopausal Estrogen and Androgen Replacement and Lipoprotein Lipid Concentrations*, AM J OBSTET GYNECOL, 1987 Feb; 156(2): 414-9.

SHERWIN, et al., *The Role of Androgen in the Maintenance of Sexual Functioning in Oophorectomized Women*, PSYCHOSOMATIC MEDICINE, 49: 397-409 (1987).

SHERWIN, *Sex Hormones and Psychological Functioning in Postmenopausal Women*, EXPERIMENTAL GERONTOLOGY, Vol. 29, pp. 423-430 (1994).

SHIFREN, et al., *Transdermal Testosterone Treatment in Women with Impaired Sexual Function After Oophorectomy*, THE NEW ENGLAND JOURNAL OF MEDICINE, Sept. 7, 2000, Vol. 343, No. 10, 682-688.

SHIRAI, et al., *Effects of Testosterone, Dihydrotestosterone and Estrogen on 3,2-Dimethyl-4-Aminobiphenyl-Induced Rat Prostate Carcinogenesis*, INT J CANCER, 1994 Apr 15; 57(2):224-8.

SIDH, et al., *Adenocarcinoma of Prostate: Role of 17beta-Estradiol and 5alpha-Dihydrotestosterone Binding Proteins*, UROLOGY, 1979 Jun; 13(6): 597-603.

SIGNORELLO, et al., *Serum Steroids in Relation to Prostate Cancer Risk in a Case-Control Study (Greece)*, CANCER CAUSES CONTROL, 1997 Jul; 8(4): 632-636.

SIMON, et al., *Percutaneous Absorption of 17 Beta-Estradiol in Ovariectomized Rhesus Monkeys: Skin and Serum Pharmacokinetics, Fertility and Sterility*, Vol. 53, No. 3, pp. 561-565 (March 1990).

SIMON, et al., *The Absorption of Oral Micronized Progesterone: The Effect of Food, Dose Proportionality, and Comparison With Intramuscular Progesterone*, Fertility and Sterility, Vol. 60, No. 1, pp. 26-33 (July 1993).

SINHA-HIKIM, et al., *The Use of a Sensitive Equilibrium Dialysis Method for the Measurement of Free Testosterone Levels in Healthy, Cycling Women and in Human Immunodeficiency Virus-Infected Women*, J CLIN ENDOCRINOL METAB, 1998 Apr; 83(4): 1312-8.

SITRUK-WARE, *Percutaneous and Transdermal Oestrogen Replacement Therapy*, Annals of Medicine, Vol. 25, pp. 77-82 (1993).

SKAKKEBAEK, et al., *Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study*, CLINICAL ENDOCRINOLOGY (1981) 14, 49-61.

SNYDER, et al., *Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age*, THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol.84, No. 6, pp. 1966-1972 (1999).

STAHL, et al., *Effects of Tamoxifen on the Levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), Prolactin (PRL), 17 beta-oestradiol (E2), Total and Free Testosterone (T) and Total and Free Dihydrotestosterone (DHT) in blood of Patients with Benign Prostatic Hyperplasia*, EXP CLIN ENDOCRINOL, 1983 Jul; 82(1): 21-8.

STEHLI, et al., *Info . . . , Info . . . , Info . . . - Androgel*, www.mageos.iffrance.com/nade38/androgel (Downloaded 5/9/01).

Date
Considered

10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 19

of

19

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

NON PATENT LITERATUREExaminer's
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

STUDD, et al., *The Relationship Between Plasma Estradiol and the Increase in Density in Postmenopausal Women After Treatment with Subcutaneous Hormone Implants*, AM J OBSTET GYNECOL, 1990 Nov; 163(5 Pt 1): 1474-9.

STUENKEL, et al, *Sublingual Administration of Testosterone-Hydroxypropyl--Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men*, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 72, No.5, pp. 1054-1059 (1991).

SWERDLOFF, et al., *Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men*, 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).

SWERDLOFF, et al., *Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men*, Clinical Science: Reproduction (Male)-Prostate, Male Reproduction Poster Session, No. 2347 (June 22, 2000).

TENOVER, et al., *Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men*, J GERONTOL, 1988 Nov; 43(6): M163-9.

TENOVER, et al., *The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate*, J CLIN ENDOCRINOL METAB, 1987 Dec; 65(6): 1118-1126.

~~Testoderm, PHYSICIANS DESK REFERENCE, Alza 517-520.~~

TIRASSA, et al., *High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Nerve Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain*, Journal of Neuroscience Research, Vol. 47, No. 2, pp. 198-207 (January 15, 1997).

Treatments, IMPOTENCE WORLD ASSOCIATION, <http://www.impotenceworld.org/treatment.htm>.

TSAL, et al., *Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors*, J PHARM SCI, 1996 Jun; 85(6): 643-648.

TSITOURAS, *Effects of Age on Testicular Function*, ENDOCRINOLOGY AND METABOLISM CLINICS, Vol. 16, No. 4, p.1045-1059 (December 1987).

TUITEN, et al., *Time Course of Effects of Testosterone Administration on Sexual Arousal in Women*, ARCH GEN PSYCHIATRY, 2000 Feb; 57(2): 149-53.

TUTTEN, et al., *Discrepancies Between Genital Responses and Subjective Sexual Function during Testosterone Substitution in Women with Hypothalamic Amenorrhea*, PSYCHOSOM MED, 1996 May-Jun; 58(3): 234-41.

VALERO-POLITI, et al., *Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men*, CLIN CHIM ACTA, 1998 Mar 9; 271(1): 57-71.

VALERO-POLITI, et al., *Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men*, EUR J CLIN CHEM CLIN BIOCHEM, 1996 Jun; 34(6): 455-462.

VAN GAAL, et al., *Sex Hormones, Body Fat Distribution, Resting Metabolic Rate and Glucose-Induced Thermogenesis in Premenopausal Obese Women*, INT J OBES RELAT METAB DISORD, 1994 May; 18(5): 333-.

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 30 of 19

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

NON PATENT LITERATURE

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

- VAN HONK, et al., Correlations Among Salivary Testosterone, Mood, and Selective Attention to Threat in Humans, HORM BEHAV, 1999 Aug; 36(1): 17-24.*
- VAUBOURDOLLE, et al., Effect of Dihydrotestosterone on the Rate of Ethanol Elimination in Healthy Men, Alcohol Clin. Exp. Res., Vol. 15, No. 2, pp. 238-240 (March 1991).*
- VELDHUIS, et al., Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men, The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 2, pp. 529-535. (2001)*
- VERGEL, Anabolic Steroids: A Practical Guide, CRIA Update, Vol. 7, No. 3 (Summer 1998).*
- VERMEULEN, et al., Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins, MATURITAS, 7 (1985) 281-287.*
- VERMEULEN, et al., Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins, MATURITAS, 7 (1985) 281-287.*
- VOIGT, et al., The Role of Tissue Steroids in Benign Hyperplasia and Prostate Cancer, UROLOGE [A], 1987 Nov; 26(6):349-57.*
- WALTERS, Penetration Enhancers and Their Use in Transdermal Therapeutic Systems, pp. 202-227 (1990).*
- WANG, C., et al., Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men □ A Clinical Research Center Study, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 81, No. 10, pp. 3654-3662 (1996).*
- WANG, C., et al., Testosterone Replacement Therapy Improves Mood in Hypogonadal Men, A Clinical Research Center Study, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 81, No. 10, pp. 3578-3583 (1996).*
- WANG, et al., Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men, A Clinical Research Center Study, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 83, No. 8, pp 2749-2757 (1998).*
- WANG, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men, 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).*
- WANG, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men, Clinical Endocrinology, Vol. 54, pp. 1-13 (2001).*
- WANG, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men, Clinical Science: Reproduction (Male)-Prostate, Male Reproduction Poster Session, No. 2348 (June 22, 2000)*
- WANG, et al., Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study, THE JOURNAL OF ENDOCRINOLOGY AND METABOLISM, Vol. 85, No. 3, pp 964-969 (2000).*
- WANG, et al., PHARMACOKINETICS OF TRANSDERMAL TESTOSTERONE GEL IN HYPOGONADAL MEN, ENDO □ 98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.*
- WANG, et al., Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone, J CLIN ENDOCRINOL METAB, 1981 Nov; 53(5): 1021-1024.*

Date
Considered

10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

NON PATENT LITERATURE

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

- 540
- WANG, et al., *Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men*, Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).
- WATTS, et al. *Comparison of Oral Estrogens and Estrogens Plus Androgen on Mineral Density, Menopausal Symptoms, and Lipid-Lipoprotein Profiles in Surgical Menopause*, OBSTET GYNECOL, 1995 Apr; 85(4):529-37.
- WEINBAUER, et al., *Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihydrotestosterone Enanthate in Non-Human Primates*, ACTA ENDOCRINOLOGICA (COPENH) 1990, 122, 4: 432-442.
- WILLEMSE, et al., *No Change in Plasma Free Testosterone Ratio and Plasma Sex Hormone-Binding Globulin Concentration During hCG Stimulation*; J CLIN ENDOCRINOL METAB, 1984 Jun; 58(6): 1193-1196.
- WILSON, *The Pathogenesis of Benign Prostatic Hyperplasia*, AM J MED, 1980 May; 68(5): 745-56.
- WINTERS, et al., *Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence that Ageing Enhances Testosterone Negative Feedback*. The Testoderm Study Group, CLIN ENDOCRINOL (Oxf) 1997 Sep; 47(3): 317-322.
- WINTERS, *The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men*; METABOLISM, 1984 Nov; 33(11): 1052-1059.
- WOODFORD, et al., *Optimization of Bioavailability of Topical Steroids: Thermodynamic Control*, The Journal of Investigative Dermatology, Vol. 79, No. 6, pp. 388-391 (December 1982).
- YU, et al., *Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men*; J CLIN PHARMACOL, 37:1139-1145 (1997).
- YU, et al., *Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application*, J CLIN PHARMACOL, 37:1129-1138 (1997).
- ZAMBERLAN, et al., *Effect of Hyperandrogenism and Menstrual Cycle Abnormalities Bone Mass and Bone Turnover in Young Women*, CLIN ENDOCRINOL (OXF), 1998 Feb; 48(2): 169-73.
- ZARTARIAN, et al., *Comparative Evaluation of the Acceptability of a New Estradiol Gel TX11323(A) and a Reference Gel*, J. Gynecol. Obstet. Biol. Reprod. (Paris), Vo. 25, No. 5, pp. 451-456 (1996).
- ZEGINIADOU, et al., *NonLinear Binding of Sex Steroids to Albumin and Sex Hormone Binding Globulin*, EUR J DRUG METAB PHARMACOKINET, 1997 Jul; 22(3): 229-235.
- ZMUDA, et al., *Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men*, METABOLISM, 1996 Aug; 45(8): 935-939.
- "Alternative to Viagra For Women!", www.mdhealthline.com (Downloaded 8/7/00).
- "Anabolic Steroid Boosts Weight", GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).
- ~~"Anabolic Steroids—A Simple Facts Sheet From The Network", www.network/simple/steroids (Downloaded 10/27/98).~~
- ~~"Anabolic Steroids", Project Inform Hotline Handout, www.projinf.org (Downloaded 10/8/98).~~
- ~~"Anabolic Steroids", Project Inform, Anabolic Steroids Quick Sheet (December 1997).~~
- ~~"Andro-Gel", NETRITION, http://www.netrition.com/andro_gel_page.html.~~

Date
Considered

10/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

Sheet 18 of 19

NON PATENT LITERATUREExaminer
Initials*Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

	"Androgel - Phase III Clinical Trial", Gynecology (Updated)
	"Androgel 1% (testosterone gel) CIII", www.Androgel.com, pp. 1-2
	"Androgel Package Insert", Dec. 2000
	"Androgel, Information Release" date unknown
SED	"Androgel", The Medical Letter On Drugs And Therapeutics, Vol. 42 (Issue 1080), pp. 49-52 (June 12, 2000).
	"AndrosteDERM", http://www.gethuge.net/androderm1.htm
SED	"Bentley Pharmaceuticals Announces License Agreement for Its Topical Testosterone Gel Formulation"; Li, www.UVentures.com (December 18, 2000).
	"Bentley Pharmaceuticals Announces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy", www.bentleypharm.com (downloaded 11/17/01).
	"Cellegy Pharmaceuticals Market Opportunities", CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html
SED	"Clinical Applications of Androgens", 43:449-457, 1996 Wiley-Liss, Inc.
SED	"Data Supports Safety of Estratest For Men, Doctor's Guide", www.pslgroup.com (March 9, 1998).
SED	"Graeme's Testosterone Page", http://www.voyager.co.nz/~gtuck/graeame/
SED	"HIV Wasting Syndrome", www.thebody.com (May 1997).
SED	"HIV Wasting Treatment: Nandrolone Decanoate", www.hivinsite.ucsf.edu (August 1, 1995).
SED	"HIV/AIDS Clinical Trials in the New Orleans Area, ACTG 329", www.tmc.tulane.edu (Downloaded 10/8/98).
SED	"International Search Report - Application No. PCT/US 01/27199", Reference No. 01902267 (International Filing Date: 08/29/2001).
	"International Search Report - Application No. PCT/US 01/27202", Reference No. 01736571 (International Filing Date: 08/29/2001).
SED	"International Search Report - Application No. PCT/US 01/27205", Reference No. 01736544 (International Filing Date: 08/29/2001).
	"La Sexualite . . . , L'Androgel, Le Gel Miracle", www.aci-multimedia.net/feminin/androgel (Downloaded 5/9/01).
	"Los Gatos Longevity Institute, Andropausal", http://www.antiaging.com/andropause.html
	"Male Hormone Patch Approved", NUPHARM, http://www.nupharm.com/malehorm.htm
	"Menopause and Testosterone", www.womenshealth.com (Downloaded 8/7/00).
	"Never Too Buff", Time Europe, www.time.com, Vol. 155, No. 16 (April 24, 2000).
SED	"Press Release - 10/21/99 -- MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA, Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone", http://www.mchm.com/press/pr24.asp
SED	"Product Information - Testoderm T.T.S.", PHYSICIANS' DESK REFERENCE, Alza/517-520
SED	"Prospectus - Cellegy Pharmaceuticals, Inc.", OPPENHEIMER & CO., 1997.

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with patent communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/033,101
Filing Date	10/19/2001
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	Jiang, S.
Attorney Docket Number	01917590

Sheet 19 of 19

NON PATENT LITERATURE


Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		"Sepa Testosterone Transdermal Gel Receives Application by FDA", DOCTOR'S GUIDE GLOBAL EDITION, http://pslgroup.com/dg/123aa.htm .
SD		"Sex, Hormones, and Hysterectomies", THE NEW ENGLAND JOURNAL OF MEDICINE, Sept. 7, 2000, Vol. 343, No. 10, 730-731.
SD		"Sexual Dysfunction in the Male, Sexual Arousal Disorder", THE MERCK MANUAL, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).
		"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available, INTERNATIONAL Association of Physicians in AIDS Care", http://www.iapac.org/clinmgmt/compnews/sb061297.html .
		"Testocrema - No Shots, No Pills, No Patches", www.testocrema.com (Downloaded 7/10/00).
SD		"Testosterone 'Aids Post-Menopausal Women', BBC News Online: Health", www.bbc.co.uk . (June 14, 1999).
SD		"Testosterone Gel May Help Men with Low Sex Drive", THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS, Vol. 42 (Issue 1080), pp. 49-52 (June 12, 2000).
		"Testosterone Gel May Help Men with Low Sex Drive", WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ .
		"Testosterone Patch Increases Women's Sex Drive," http://abcnews.go.com/sections/living/DailyNews/testosterone990615.html .
SD		"Testosterone Therapy - for Women?", Health News, www.onhealth.com (May 7, 1996).
SD		"Testosterone's Role in the Female Sex Drive", USA Today News, www.usatoday.com (April 8, 1996).
		"Testosterone", Chapters 1-16 (1999).
		"Testosterone", PREVENTIVE MEDICINE CLINIC OF MONTEREY, http://www.wellnessmd.com/testo.html .
		"The Testosterone Source", http://www.testosteronesource.com .
		"Trials for the Treatment of Wasting", AIDS Treatment Data Network, www.aidsinfonyc.org (Downloaded 10/8/98).
SD		"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men", Fertility Industry News, www.INCIID.com (August 19, 1998).
		"USP Drug Information - Anabolic Steroids (Systemic)", MayoClinic, www.mayohealth.org (Downloaded 10/8/98).
SD		"Women and HIV", Women and HIV Discussion Paper, pp. 1-12 (1/98).

Date
Considered

10/8/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



#12

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/033,101
				Filing Date	October 19, 2001
				First Named Inventor	Robert E. DUDLEY
				Art Unit	1617
Examiner Name	S. JIANG				
Sheet	1	of	1	Attorney Docket Number	01917590

TECH CENTER 1600/2900
AUG 08 2003

RECEIVED

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SJD	1	4,663,157	05-05-87	Brock, E.D.	
	2	4,699,779	10-13-87	Palinczar, V.	
	3	5,023,252	06-11-91	Hsieh, D.	
	4	5,446,025	08-29-95	Lu, M.F.	
	5	5,731,303	03-24-98	Hsieh, D.	
	6	5,891,462	04-06-99	Carrara, D.	
	7	6,503,894	01-07-03	Dudley, R.E.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SPD	8	AU 4998490	09-20-90	Amway Corp.		
	9	AU 9141391	06-25-92	Theratech Inc.		
	10	EP 189861	08-06-86	Showa Denko		
	11	EP 332147	09-13-89	Warner-Lambert		
	12	EP 552405	11-25-98	Lintec Corp.		
	13	EP 811381	05-02-03	Permotech N.V.		
	14	GB 1158283	07-16-69	Foster-Milburn		
	15	JP 62-011675	08-02-94	TEZUKA		
	16	WO 87/03473	06-18-87	Hsieh, D.		
	SPD	17	WO 92/07586	05-14-92	Beecham Group PLC	

Examiner Signature	<i>SJD</i>	Date Considered	10/8/03
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/033,101
Filing Date	October 19, 2001
First Named Inventor	Robert E. DUDLEY
Art Unit	1617
Examiner Name	S. JIANG
Attorney Docket Number	01917590

RECEIVED
AUG 08 2003
TECH CENTER 1600/2800

NON PATENT LITERATURE

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJD	1	DELANOE et al., "Androgenisation of Female Partners of Men on Medroxyprogesterone Acetate/Percutaneous Testosterone Contraception," The Lancet (Feb 1984), p. 276.	
	2	DEMERY, A. "Contraception Masculine" Soins Gyn.-Obs.-Puer.-Ped., No. 72 (May 1987) pp. 33-38.	
	3	MARBURY et al., "Evaluation of the Pharmacokinetic Profiles of the New Testosterone Topical Gel Formulation, Testim(TM), Compared to AndroGel(R)," Biopharm. Drug Dispos., 24:115-120 (2003).	
	4	MORGAN et al., "Enhanced Skin Permeation of Sex Hormones with Novel Topical Spray Vehicles," J. Pharm. Science (1998) Vol. 87 No. 10, pp. 1213-1218.	
	5	MORGAN et al., "Enhanced Transdermal Delivery of Sex Hormones in Swine with a Novel Topical Aerosol," J. Pharm. Science (1998) Vol. 87 No. 10, pp. 1219-1225.	
	6	POPE JR., et al., "Testosterone Gel Supplementation for Men with Refractory Depression: A Randomized, Placebo-Controlled Trial," Am. J. Psychiatry, 160(1): 105-111 (2003).	
	7	SCHOOR, M., "Livening Up Libidos: Testosterone Patches Can Help Revive Women's Sex Drive," www.abcnews.com, September 6, 2000.	
	8	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-K) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1998, filed on March 22, 1999.	
	9	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-K) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1999, filed on March 14, 2000.	
	10	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-KSB) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1996, filed on March 28, 1997.	
	11	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-KSB) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1997, filed on March 31, 1998.	
	12	CELLEGY PHARMACEUTICALS, INC.: INVESTORS: PRESS RELEASES, "Cellegy Pharmaceuticals Receives FDA Nonapproval Letter for Fortigel," July 7, 2003, www.cellegy.com.	
	13	PERCUTACRINE STRONG ANDROGENIC Testosterone Percutacrine Androgenique Forte from VIDAL dictionary (1985).	X
	14	Protest Under 37 CFR 1.291(a) of U.S. Patent Application No. 09/651,777 dated August 20, 2002.	

Examiner Signature		Date Considered	10/8/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.